By physician referral or invitation only

Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

To compare the safety and effectiveness of the study drug TAK-881 to the common drug HYQVIA.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Rebecca Traub
Neurology-Neuromuscular

Study Type

Clinical or Medical
Interventional

Study Topics

Brain, Head, Nervous System
Chronic Conditions

IRB Number

25-0363

ClinicalTrials.gov

NCT06747351

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.